Anthem Biosciences Limited has informed the Exchange of a change in management, subject to the approval of the Shareholders in the ensuing Annual General Meeting, arising from (i) the proposed re-appointment of Mr. K Ravindra Chandrappa, director retiring by rotation, and (ii) the continuation of Mr. Ravikant Uppal, Independent Director for the remainder of the tenure approved in the 19th AGM dated June 10, 2025.

Anthem Biosciences Limited reported strong FY2026 results with standalone revenue of Rs 2,089 crore and net profit of Rs 570 crore, while consolidated revenue stood at Rs 2,120 crore with net profit of Rs 568 crore. The Board recommended a final dividend of Rs 2 per equity share and scheduled the 20th AGM for July 22, 2026. The company also allotted 14.81 lakh equity shares under its ESOP 2024 scheme, increasing paid-up capital to Rs 112.64 crore. Key management items include recommending continuation of Mr. Ravikant Uppal as Independent Director (who turns 75 in May 2027) and re-appointment of Mr. Ravindra Chandrappa as Whole-Time Director retiring by rotation, both subject to shareholder approval at the AGM.